Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Rating of “Hold” by Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has received a consensus rating of “Hold” from the six ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $5.00.

Separately, Wells Fargo & Company started coverage on shares of Zentalis Pharmaceuticals in a report on Tuesday. They set an “equal weight” rating and a $5.00 price objective on the stock.

Zentalis Pharmaceuticals Trading Down 7.7%

Shares of Zentalis Pharmaceuticals stock opened at $2.52 on Thursday. The firm’s 50 day simple moving average is $2.68 and its two-hundred day simple moving average is $1.91. The firm has a market capitalization of $182.07 million, a price-to-earnings ratio of -1.22 and a beta of 1.71. Zentalis Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $3.95.

Insider Transactions at Zentalis Pharmaceuticals

In other news, major shareholder Group Walters bought 6,459,973 shares of the firm’s stock in a transaction that occurred on Wednesday, December 31st. The stock was purchased at an average price of $1.20 per share, with a total value of $7,751,967.60. Following the completion of the acquisition, the insider directly owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. This trade represents a 91.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Vincent Vultaggio sold 29,951 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the completion of the sale, the insider owned 156,779 shares in the company, valued at approximately $380,972.97. This represents a 16.04% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 46,617 shares of company stock valued at $113,417. 1.90% of the stock is currently owned by insiders.

Institutional Trading of Zentalis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. lifted its stake in Zentalis Pharmaceuticals by 8.6% during the 4th quarter. Invesco Ltd. now owns 188,582 shares of the company’s stock valued at $255,000 after acquiring an additional 14,961 shares during the period. XTX Topco Ltd increased its stake in shares of Zentalis Pharmaceuticals by 5.1% in the fourth quarter. XTX Topco Ltd now owns 576,707 shares of the company’s stock worth $779,000 after acquiring an additional 28,078 shares during the period. Quadrature Capital Ltd raised its holdings in shares of Zentalis Pharmaceuticals by 126.8% during the fourth quarter. Quadrature Capital Ltd now owns 137,568 shares of the company’s stock worth $186,000 after purchasing an additional 76,917 shares during the last quarter. Opaleye Management Inc. raised its holdings in shares of Zentalis Pharmaceuticals by 342.6% during the fourth quarter. Opaleye Management Inc. now owns 1,400,906 shares of the company’s stock worth $1,891,000 after purchasing an additional 1,084,356 shares during the last quarter. Finally, Ishara Investments LP acquired a new position in Zentalis Pharmaceuticals during the fourth quarter valued at $1,782,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.